Entrada Therapeutics, Inc.TRDANASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -55.25% | -10.63% | -65.23% | -97.94% | -91.75% |
| Gross Profit Growth | -9.16% | -10.63% | -65.23% | -97.94% | -287.77% |
| EBITDA Growth | -239.57% | -186.42% | -194.54% | -184.32% | +0.00% |
| Operating Income Growth | -254.57% | -219.61% | -203.21% | -187.69% | +0.00% |
| Net Income Growth | -139.57% | +0.00% | -173.84% | -178.32% | +0.00% |
| EPS Growth | -132.71% | +0.00% | -160.00% | -164.60% | +0.00% |
| EPS Diluted Growth | -134.31% | +0.00% | -161.76% | -167.10% | +0.00% |
| Weighted Average Shares Growth | +22.08% | +22.40% | +22.62% | +20.94% | +2.05% |
| Weighted Average Shares Diluted Growth | +16.84% | +29.01% | +18.06% | +16.42% | +2.05% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | -174.03% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | -176.74% | +0.00% |
| Receivables Growth | -48.20% | -37.39% | -97.36% | -84.62% | +22.78% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +14.34% | +12.18% | -4.77% | -22.88% | -25.55% |
| Book Value per Share Growth | +40.29% | +44.51% | +26.33% | -27.01% | -20.97% |
| Debt Growth | -11.23% | -13.22% | -14.20% | -15.05% | -14.54% |
| R&D Expense Growth | +40.85% | +18.08% | +12.12% | +18.24% | +22.73% |
| SG&A Expenses Growth | +32.38% | +13.95% | +9.31% | +18.25% | +3.34% |